FDA has approved CDK4/6 inhibitors in HER2-negative, ER-positive postmenopausal breast cancer patients, which can block the binding site of cell cycle protein D1 on CDK4/6 thereby inhibiting tumor cell proliferation. Here, ERBB2 is linked to breast cancer.